Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small-Molecule Antagonists of CCR5 and CXCR4: A Promising New Class of Anti-HIV-1 Drugs

1 Jul 2004

Abstract excerpt

Combination therapy with reverse transcriptase and protease inhibitors greatly reduces morbidity and mortality in HIV-1-infected individuals. However, current anti-retroviral treatment cannot eradicate the virus from infected individuals and is often limited by the emergence of drug-resistant HIV-1 strains and long-term toxicity. These problems emphasize the need to develop new anti-HIV-1 drugs targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemical Synthesis and Analysis
Share to Monoclonal and Polyclonal Antibodies Research
Share to Synthesis and biological activity

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15279544
DOI: 10.2174/1381612043384312

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small-Molecule Antagonists of CCR5 and CXCR4: A Promising New Class of Anti-HIV-1 DrugsPMID 15279544Read ↗

Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseasesSemantic proximity Read ↗

Interaction of small molecule inhibitors of HIV-1 entry with CCR5Semantic proximity Read ↗

Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 EntrySemantic proximity Read ↗

The Expanding Therapeutic Perspective of CCR5 BlockadeSemantic proximity Read ↗

CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV InfectionSemantic proximity Read ↗

The biology of CCR5 and CXCR4Semantic proximity Read ↗

Maraviroc: a review of its use in HIV infection and beyond.Semantic proximity Read ↗

Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics.Semantic proximity Read ↗

CXCR4 Is a Potential Target for Anti-HIV Gene TherapySemantic proximity Read ↗

Structural and Molecular Interactions of CCR5 Inhibitors with CCR5Semantic proximity Read ↗

Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonistsSemantic proximity Read ↗

Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.